Olvance M 50 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Metoprolol Succinate 50 mg. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. This combination is indicated for the management of hypertension, especially in patients who require multiple agents to achieve optimal blood pressure control. Olvance M 50 Tablet helps in reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. It is generally well tolerated but should be used with caution in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects may include dizziness, fatigue, and hypotension. Dosage should be individualized based on patient response and tolerability, and it is essential to monitor blood pressure and heart rate regularly during therapy. This medication should be used under medical supervision with consideration of contraindications and potential drug interactions.